316 filings
Page 6 of 16
8-K
u8ijx
13 Jul 20
Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study
8:33am
EFFECT
ze4z9dcyu2
6 Jul 20
Notice of effectiveness
12:15am
CORRESP
6mbti1s8enlk5l40y
1 Jul 20
Correspondence with SEC
12:00am
UPLOAD
x81k793tau4 a39
1 Jul 20
Letter from SEC
12:00am
CORRESP
evfg270
1 Jul 20
Correspondence with SEC
12:00am
8-K
xe8e8p2
12 Jun 20
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
9s8affki
20 May 20
Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock
4:04pm
424B5
4dcjhia6nqb
20 May 20
Prospectus supplement for primary offering
4:03pm
424B5
ujty0gu
20 May 20
Prospectus supplement for primary offering
4:02pm
424B5
fnaddb33bmp658gr
18 May 20
Prospectus supplement for primary offering
4:02pm
8-K
3q75ufrm
11 May 20
Bellerophon Provides Clinical Program Update and Reports First Quarter 2020 Financial Results
4:03pm
8-K
3hg84
11 May 20
Bellerophon Therapeutics Announces FDA Clears Initiation of Phase 3 Study for INOpulse® Inhaled Nitric Oxide Therapy to Treat COVID-19
8:29am
DEFA14A
x2sn3u0ao d3fd2f
27 Apr 20
Additional proxy soliciting materials
4:31pm
8-K
h1tty
8 Apr 20
Other Events
8:31am
8-K
356le6v8ivtrq0myt4l
6 Apr 20
Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2019 Financial Results
8:32am
NT 10-K
y77ylnm0
31 Mar 20
Notice of late annual filing
4:10pm